CBmed projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, therapy monitoring and a more personalized treatment of patients.

AREA 1: DATA & TECHNOLOGIES

As of 2019

  • Digital biomarkers for precision medicine (DBM4PM)
  • Multi-parameter core technologies: Immunology, Digital Pathology and Metabolomics
  • FUSION Technology

2015 – 2018

  • Clinical data management for biomarker research
  • Innovative use of information for clinical care and biomarker research
  • Knowledge discovery and advanced interactive data mining
  • Next generation sequencing-based biomarkers in molecular pathology
  • Metabolomics Platform for biomarker research
  • Immunology Platform for biomarker research
  • Health technology assessment
  • Digital Pathology
  • Clinical MALDI application

AREA 2: CANCER

As of 2019

  • Liquid biopsy in cancer
  • Translational molecular imaging agents for in-vitro and in-vivo application
  • Next-generation drug-screening platform for precision oncology services
  • Near-infrared light exposure in cancer

2015 – 2018

  • Circulating tumour cells and cell-free nucleic acids as biomarkers for disease monitoring
  • Tracking the trace: Detection, selection and target evaluation of cellular and cell-free cancer biomarkers
  • Blood based, broad-spectrum biomarker panels for cancer diagnostics
  • Minimal residual disease detection as a prognostic biomarker and therapeutic target in hematologic malignancies using monoclonal antibodies and development of therapeutic chimeric antibody receptor (CAR) T cells
  • Genomic, transcriptomic and proteomic evaluation of eukaryotic initiation factors (eIFs) in various tumour entities
  • Galpha12 and Galpha13 as prognostic biomarkers and inducers of apoptosis in solid cancers
  • MR-PDX-models for the evaluation of cancer treatments
  • Core Lab for target identification and in-vivo probe development
  • Fusion Technology: Colon Cancer Stage 2

AREA 3: CARDIO-METABOLIC HEALTH

As of 2019

  • Biomarkers for cardiometabolic health and disease
  • Biomarkers in acute cardio-reno-metabolic disease states
  • Diagnostic and predictive biomarkers in disorders of fertility and metabolism
  • Microbiome-based biomarkers

2015 – 2018

  • Biomarkers to address diabesity
  • Biomarkers in early detection and risk assessment of cardiovascular disease
  • Biosensors for short-lived biomarkers
  • Biomarkers of bone metabolism and related organ systems
  • Biomarkers in the regulation of fertility
  • Minimally-invasive biomarkers for liver function
  • In-vivo biomarkers for inflammation and fibrosis diagnosis and therapy monitoring
  • Minimally-invasive broad spectrum biomarkers for NAFLD diagnosis and monitoring
  • Biomarkers for probiotic effects on microbiome-gut-brain axis
  • Biomarkers for early sepsis detection
  • Molecular signatures as biomarkers of invasive fungal infections
  • Electrochemical biomarkers‚ detection in common metabolic disorders

> 50 INTERNATIONAL PARTNERS ON 4 CONTINENTS

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast